Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
san francisco blog main
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
boston blog main
boston top stories
cannabidiol
dravet syndrome
drugs
duchenne muscular dystrophy
dyne therapeutics
epidiolex
facioscapulohumeral muscular dystrophy
fda
fen-phen
fenfluramine
gene therapy
gw pharmaceuticals
joshua brumm
kaleido biosciences
lennox-gastaut syndrome
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
romesh subramanian
san diego blog main
san francisco
san francisco top stories
susanna high
vertex pharmaceuticals
zogenix
What
ago
2
×
data
2
×
drug
2
×
rare
approved
battle
biotechs
cannabis
considering
derivative
diseases
dyne
early
epilepsy
expected
experimental
eyes
fda
form
genetic
gw
gw’s
having
humans
ipo
ipos
long
marijuana
market
medicine
medicines
muscle
pharmaceuticals
reach
sets
therapeutics
weeks
worked
zogenix
Language
unset
Current search:
ago
×
drug
×
data
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug